Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.31 |
| ▸ | PRCP | P42785 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7970250 | 0.71 | CYP3A4 (0.33) | SMN1; SMN2ALDH1A1GID4 | |
| SCHEMBL6054586 | 0.70 | — | — | |
| SCHEMBL28780384 | 0.68 | TSHR (0.35) | TSHRSLC18A3SIGMAR1GID4PRCP | |
| SCHEMBL5279733 | 0.67 | TSHR (0.42) | TSHRSMN1; SMN2ALDH1A1CA2EPHX1 | |
| SCHEMBL3628911 | 0.67 | — | — | |
| SCHEMBL22686800 | 0.67 | SMN1; SMN2 (0.37) | SMN1; SMN2KDM4EALDH1A1HPGDCA2 | |
| SCHEMBL19382438 | 0.65 | EPHX1 (0.40) | TSHRCA2EPHX1SLC18A3SIGMAR1 | |
| SCHEMBL6465848 | 0.63 | — | — | |
| SCHEMBL28890875 | 0.63 | CA2 (0.47) | SMN1; SMN2KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL22063723 | 0.62 | TSHR (0.33) | TSHRCA2EPHX1SLC18A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3133061-B1 | FLORFENICOL SYNTHESIZING METHOD | MASTEAM BIO TECH CO LTD (CN) | 2024-03-20 | — | — | EP | disclosed |
| EP-3138844-B1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | EISAI R&D MAN CO LTD (JP) | 2018-05-02 | — | — | EP | disclosed |
| EP-3138844-A1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | Eisai R&D Management Co., Ltd. (JP) | 2017-03-08 | — | — | EP | disclosed |
| EP-3133061-A1 | FLORFENICOL SYNTHESIZING METHOD | Masteam Bio-tech Co. Ltd. (CN) | 2017-02-22 | — | — | EP | disclosed |
| EP-1910387-B1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | EISAI R&D MAN CO LTD (JP) | 2016-11-16 | — | — | EP | disclosed |
| EP-2776430-B1 | 2- (1,2,3-TRIAZOL-2-YL) BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL) PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-03-16 | — | — | EP | disclosed |
| US-8962857-B2 | Compounds for preparing immunological adjuvant | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-20140323739-A1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | Eisai R&D Management Co.. Ltd. (JP) | 2014-10-30 | — | — | US | disclosed |
| US-8754236-B2 | Compounds for preparing immunological adjuvant | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| US-20140012011-A1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-01-09 | — | — | US | disclosed |
| US-8519170-B2 | Compounds for preparing immunological adjuvant | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| US-20120232298-A1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | FANG FRANCIS G (US) | 2012-09-13 | — | — | US | disclosed |
| US-8198474-B2 | Compounds for preparing immunological adjuvant | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| EP-2292628-A2 | Compounds for preparing immunological adjuvant | Eisai R&D Management Co., Ltd. (JP) | 2011-03-09 | — | — | EP | disclosed |
| US-20100197951-A1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-7683200-B2 | Compounds for preparing immunological adjuvant | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-03-23 | — | — | US | disclosed |
| EP-1910387-A1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | Eisai Co., Ltd (JP) | 2008-04-16 | — | — | EP | disclosed |
| US-20070082875-A1 | toll-like receptor-4 agonists; vaccines | EISAI CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
| WO-2007005583-A1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | EISAI CO., LTD. (JP) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197951-A1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | TLR4, TLR3, TLR1 | TSHR 1777/4885SMN1; SMN2 2638/4885KDM4E 1305/4885 |
| US-20070082875-A1 | toll-like receptor-4 agonists; vaccines | TLR4, TLR3, TLR1 | TSHR 564/4885SMN1; SMN2 2592/4885KDM4E 1979/4885 |
| US-20140323739-A1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | TLR4, TLR3, TLR1 | TSHR 1563/4885SMN1; SMN2 2517/4885KDM4E 1444/4885 |
| US-20120232298-A1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | TLR4, TLR3, TLR1 | TSHR 1563/4885SMN1; SMN2 2517/4885KDM4E 1444/4885 |
| US-20140012011-A1 | COMPOUNDS FOR PREPARING IMMUNOLOGICAL ADJUVANT | TLR4, TLR3, TLR1 | TSHR 1563/4885SMN1; SMN2 2517/4885KDM4E 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.